CD4 and neoplasm: Preclinical evidence showed that PI3Kδ inhibition directly affects the leukemic B cells, whereas PI3Kγ inhibition targets key support cells in the tumor protective niche, such as CD4+ T cells and M2 tumor-associated macrophages [34,46] (Figure 1).